New Delhi: Sun Pharmaceutical Industries and the National Institute of Virology (NIV), Pune recently signed an agreement for testing phytopharmaceutical, biologic and chemical entities developed by Sun Pharma against Zika, chikungunya and dengue viruses. Sun Pharma will provide drug molecules to NIV for testing against Zika, chikungunya and dengue viruses.
The phytopharmaceuticals are being developed for treating individuals infected with Zika virus and possibly for curing Zika disease.These phytopharmaceutical candidates have been isolated from plants found in India. In the case of chikungunya, Sun Pharma has identified certain chemical entities in house which would be tested at NIV. The drug molecules will be tested against all the three viruses through laboratory studies (in vitro) and the promising candidates will be tested on animals.
Zika, chickungunya and dengue viruses are transmitted to humans by infected Aedes mosquitoes.